Recommandations du groupe Fi-LMC pour la gestion des effets indésirables du traitement par nilotinib (Tasigna®) au cours de la leucémie myéloïde chronique-Reference-Cited by-同舟云学术

Recommandations du groupe Fi-LMC pour la gestion des effets indésirables du traitement par nilotinib (Tasigna®) au cours de la leucémie myéloïde chronique

Published:2010-08 Issue:8 Volume:97 Page:997-1009
ISSN:0007-4551
Container-title:Bulletin du Cancer
language:fr
Short-container-title:Bulletin du Cancer

Author:

Étienne G.,Milpied B.,Réa D.,Rigal-Huguet F.,Tulliez M.,Nicolini F.-E.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Reference23 articles.

1. Treatment of chronic myeloid leukemia in 2007;Labussière;Bull Cancer,2007

2. Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL;Kantarjian;NEJM,2006

3. Final safety analysis of 1,793 cml patients from ENACT (expanding nilotinib access in clinical trials) study in adult patients with imatinib-resistant or intolerant Chronic myeloid leukemia;Nicolini;Haematologica,2009

4. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine-kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance;Kantarjian;Blood,2007

5. Nilotinib for the frontline treatment of Ph+chronic myeloid leukemia;Rosti;Blood,2009

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of chronic myeloid leukemia (CML) in pregnant women: a comprehensive literature review;Annals of Blood;2024-03

2. The Effects of Tyrosine Kinase Inhibitors (TKIs) in Monotherapy and with Add-on Treatments on Health-related Quality of Life of People with Chronic Myeloid Leukemia: A Systematic Review of Randomized-Controlled Trials;Clinical Practice & Epidemiology in Mental Health;2023-01-05

3. Managing Pregnancy in Chronic Myeloid Leukaemia;Hematologic Malignancies;2021

4. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia;Leukemia & Lymphoma;2019-01-11

5. Monitoring the safety of nilotinib in patients with chronic myeloid leukemia;Macedonian Pharmaceutical Bulletin;2019